The short version of Fatty diacid fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-25. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
=== Subcellular membrane fluidity under cold and osmotic stress === The efficiency of lactic acid bacteria cryopreservation is not consistent and may lead to cell death. Lactobacillus delbrueckii subsp. bulgaricus has adapted to defend against cold stress. The way most cells react to the cold is by changing the fluidity of the cellular membrane, but this particular bacterium has acquired different tactics to fight against cold stress. The first way to cope with the cold is to increase viscosity by taking in compounds such as disaccharides, polysaccharides, amino acids and antioxidants. The second strategy used is performed by inducing active responses during the fermentation or post-fermentation processes. By modifying these it will change the temperature, pH and medium composition. This results in specific metabolic pathways becoming active, with the synthesis of cold shock proteins.
For South Africa and the Soviet Union—the two parties which had previously refrained from joining the US-mediated talks—the point had now been reached where the costs of continuing the war exceeded its anticipated benefits. This necessitated a change in perceptions in both nations, which began warming to the possibility of a negotiated peace. The Soviet government agreed to jointly sponsor with the US a series of renewed peace talks on 3 and 4 May 1988. For its part, South Africa made its first bid to join the tripartite negotiations and agreed to send a delegation of diplomats, intelligence chiefs, and senior SADF officers. The Soviet and US diplomats in attendance, including Crocker, made it clear to the South Africans that they wanted peace in Angola and a political settlement in South West Africa. They were also agreed on the need to bring pressure on their respective allies to bring about a solution. South Africa would be expected to comply with United Nations Security Council Resolution 435, in exchange for the complete withdrawal of Cuban troops from Angola. The Cuban and Angolan delegations had already assented to a complete Cuban withdrawal, and under US pressure produced an extremely precise timetable which extended this process over three to four years. South Africa found this unacceptable but conceded that the withdrawal could be timed to certain benchmarks in the Namibian independence process. According to Crocker, the US decision to use Security Council Resolution 435 as the basis and pivot for a regional settlement provided leverage over the discussions.
nonrepetitive sequence Broadly, any nucleotide sequence or region of a genome that does not contain repeated sequences, or in which repeats do not comprise a majority; or any segment of DNA exhibiting the reassociation kinetics expected of a unique sequence.
He considered the West Midlands dialect of Middle English to be his own "native language", and, as he wrote to W. H. Auden in 1955, "I am a West-midlander by blood (and took to early west-midland Middle English as a known tongue as soon as I set eyes on it)."
Sources: en.wikipedia.org
Colombia lies at the crossroads of Latin America and the broader region of the Americas, and as such has been hit by a wide range of cultural influences. Native American, Spanish and other European, African, American, Caribbean, and Middle Eastern influences, as well as other Latin American cultural influences, are all present in Colombia's modern culture. Urban migration, industrialization, globalization, and other political, social and economic changes have also left an impression. Many national symbols, both objects and themes, have arisen from Colombia's diverse cultural traditions and aim to represent what Colombia, and the Colombian people, have in common. Cultural expressions in Colombia are promoted by the government through the Ministry of Culture.
== Awards and honours == 2007 Donald F. Steiner Award for Outstanding Diabetes Research, University of Chicago 2008 Prix Galien Canada for Outstanding Pharmaceutical Research 2009 Clinical Investigator Award, Endocrine Society 2012 Claude Bernard Prize, European Association for the Study of Diabetes 2012 Fellow of the Royal Society of Canada 2013 Oon International Award for Preventative Medicine, University of Cambridge 2014 Banting Medal for Scientific Achievement, American Diabetes Association 2014 Manpei Suzuki Foundation International Prize for Diabetes, Japan 2015 Fellow of the Royal Society 2015 Officer of the Order of Canada 2017 Rolf Luft Award in Endocrinology and Diabetes Research, Karolinska Institute 2017 Harrington Prize for Innovation in Medicine, American Society for Clinical Investigation and the Harrington Institute (co-recipient with Joel Habener and Jens Juul Holst) 2019 Harold Hamm International Prize for Biomedical Research in Diabetes 2019 Novo Nordisk Foundation and European Association for the Study of Diabetes Prize for Excellence in Diabetes Research (watch the mini documentary about Drucker produced by the Novo Nordisk Foundation for the occasion) 2019 Lifetime Achievement Award, Helmholtz Diabetes Centre, Germany 2020 John Baxter Award for Entrepreneurship, Endocrine Society 2020 Transatlantic Medal, Society for Endocrinology 2020 Warren Alpert Foundation Prize for Biomedical Research (co-recipient with Joel Habener and Jens Juul Holst) 2021 International Member, National Academy of Sciences 2021 Canada Gairdner International Award (co-recipient with Joel Habener and Jens Juul Holst) 2022 Inductee of the Canadian Medical Hall of Fame 2023 Wolf Prize in Medicine 2023 International Member of the National Academy of Medicine 2023 VinFuture Prize for Innovators with Outstanding Achievements in Emerging Fields (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2024 Princess of Asturias Award for Technical and Scientific Research (co-recipient with Jeffrey M. Friedman, Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2024 Time100 Most Influential People and Time100 Health 2024 Golden Plate Award, American Academy of Achievement 2024 Fred Conrad Koch Lifetime Achievement Award, Endocrine Society 2024 TOPS Research Achievement Award, The Obesity Society 2025 Warren Triennial Prize, Massachusetts General Hospital (co-recipient with Joel Habener and Svetlana Mojsov) 2025 BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2025 Solomon A. Berson Award, American Physiology Society 2025 Breakthrough Prize in Life Sciences (co-recipient with Joel Habener, Jens Juul Holst, Svetlana Mojsov and Lotte Bjerre Knudsen) 2026 Governor General's Innovation Award
The increasing aggressiveness of Hitler prompted the Czechoslovak military to start to build extensive border fortifications in 1936 to defend the troubled border region. Immediately after the Anschluss of Austria into the German Reich in March 1938, Hitler made himself the advocate of ethnic Germans living in Czechoslovakia, which triggered the Sudeten Crisis. The following month, Sudeten Nazis, led by Konrad Henlein, agitated for autonomy. On 24 April 1938, the SdP proclaimed the Karlsbader Programm, which demanded in eight points the complete equality between the Sudeten Germans and the Czech people. The government accepted those claims on 30 June 1938. In August, British Prime Minister Neville Chamberlain sent Lord Runciman on a mission to Czechoslovakia to see if he could obtain a settlement between the Czechoslovak government and the Germans in the Sudetenland. Runciman's first day included meetings with President Beneš and Prime Minister Milan Hodža as well as a direct meeting with the Sudeten Germans from Henlein's SdP. On the next day, he met with Dr and Mme Beneš and later met non-Nazi Germans in his hotel. A full account of his report, including summaries of the conclusions of his meetings with the various parties, which he made in person to the Cabinet on his return to the United Kingdom, is found in the Document CC 39(38). Lord Runciman expressed sadness that he could not bring about agreement with the various parties, but he agreed with Lord Halifax that the time that had been gained was important.
According to a study by the World Health Organization (WHO), between 15% and 71% of women have already been victims of domestic violence, whether physical, sexual, or psychological. In France, a partner kills his wife more than once every two days, more often by deliberate homicide than by violence resulting in death. Measures implemented to combat violence against women include government intervention as well as that of the Ministry of Education. Numerous awareness campaigns have been established in schools. The Ministry of the Interior enacted a law on March 23, 2006, to promote gender equality in education. Several associations also intervene and advocate for gender diversity.
It is revealed at the 1991 Thanksgiving dinner episode that the absent Al has had a mistress for over 20 years, for which Bev eventually divorces him. Around this time Roseanne Barr was in a public battle with her real-life parents, claiming that both had physically and sexually abused her. Barr insisted that parental abuse be incorporated into the series storyline, so it is revealed that her father was physically abusive to both her and Jackie, who lived in fear of him for most of their childhood. Upon his death, Roseanne meets with his mistress, Joan, who is unaware of Al's abusive behavior, as he had led her to believe that Roseanne and Jackie were ungrateful daughters despite his doing so much for them. At Al's funeral, after privately reading him a list of the things she hates him doing to her and Jackie, Roseanne thanks her father for giving her his humorous nature.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.